1. Home
  2. EIKN vs ARVN Comparison

EIKN vs ARVN Comparison

Compare EIKN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eikon Therapeutics Inc. Common Stock

EIKN

Eikon Therapeutics Inc. Common Stock

N/A

Current Price

$12.48

Market Cap

631.0M

Sector

Health Care

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$9.60

Market Cap

516.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIKN
ARVN
Founded
2019
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
631.0M
516.2M
IPO Year
2026
2018

Fundamental Metrics

Financial Performance
Metric
EIKN
ARVN
Price
$12.48
$9.60
Analyst Decision
Buy
Buy
Analyst Count
6
19
Target Price
$25.60
$15.05
AVG Volume (30 Days)
437.0K
878.2K
Earning Date
03-30-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
1.70
Revenue
N/A
$262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$5.49
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$6.97
52 Week High
$16.50
$14.22

Technical Indicators

Market Signals
Indicator
EIKN
ARVN
Relative Strength Index (RSI) 56.76 60.31
Support Level $10.82 $7.90
Resistance Level $12.16 $9.65
Average True Range (ATR) 1.02 0.31
MACD 0.15 0.04
Stochastic Oscillator 40.89 77.27

Price Performance

Historical Comparison
EIKN
ARVN

About EIKN Eikon Therapeutics Inc. Common Stock

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: